DE68914698D1 - Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. - Google Patents
Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.Info
- Publication number
- DE68914698D1 DE68914698D1 DE68914698T DE68914698T DE68914698D1 DE 68914698 D1 DE68914698 D1 DE 68914698D1 DE 68914698 T DE68914698 T DE 68914698T DE 68914698 T DE68914698 T DE 68914698T DE 68914698 D1 DE68914698 D1 DE 68914698D1
- Authority
- DE
- Germany
- Prior art keywords
- pharmacokinetics
- proteins
- charge
- modification
- changing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/157,273 US5322678A (en) | 1988-02-17 | 1988-02-17 | Alteration of pharmacokinetics of proteins by charge modification |
Publications (2)
Publication Number | Publication Date |
---|---|
DE68914698D1 true DE68914698D1 (de) | 1994-05-26 |
DE68914698T2 DE68914698T2 (de) | 1994-08-25 |
Family
ID=22563038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE68914698T Expired - Lifetime DE68914698T2 (de) | 1988-02-17 | 1989-02-17 | Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. |
Country Status (5)
Country | Link |
---|---|
US (1) | US5322678A (de) |
EP (1) | EP0329185B1 (de) |
JP (1) | JPH0228200A (de) |
AU (1) | AU621342B2 (de) |
DE (1) | DE68914698T2 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2518911B2 (ja) * | 1987-10-23 | 1996-07-31 | 森永乳業株式会社 | c―fms癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法 |
US5635180A (en) * | 1988-02-17 | 1997-06-03 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
ATE136224T1 (de) * | 1989-09-29 | 1996-04-15 | Neorx Corp | Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten |
US5130129A (en) * | 1990-03-06 | 1992-07-14 | The Regents Of The University Of California | Method for enhancing antibody transport through capillary barriers |
US5105528A (en) * | 1991-01-22 | 1992-04-21 | Universal Instruments Corporation | Method and apparatus for supplying and changing tips of a pick and place vacuum spindle |
US5869457A (en) * | 1991-03-11 | 1999-02-09 | Rijksuniversiteit Te Groningen | Modified proteins and their use for controlling viral infections |
WO1994007138A1 (en) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
NO180658C (no) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
CA2190727C (en) * | 1994-05-19 | 2006-07-18 | Sudhakar Kasina | Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging |
US5827498A (en) * | 1994-06-07 | 1998-10-27 | Nihon Medi-Physics Co., Ltd. | Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide |
US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
GR950100415A (en) * | 1995-11-21 | 1997-07-30 | Antisoma Ltd | Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide |
NO961031D0 (no) * | 1996-03-13 | 1996-03-13 | Det Norske Radiumshospital Tum | Fremgangsmåte til å drepe uönskede målceller |
US6211150B1 (en) * | 1996-07-19 | 2001-04-03 | Amgen Inc. | Analogs of cationic proteins |
US6271364B1 (en) | 1999-02-23 | 2001-08-07 | Amgen Inc. | Analogs of NT-3 |
US6005083A (en) | 1997-03-28 | 1999-12-21 | Neorx Corporation | Bridged aromatic substituted amine ligands with donor atoms |
CA2295980A1 (en) * | 1997-06-09 | 1998-12-17 | Childrens Hospital Los Angeles | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
US6991788B1 (en) | 1997-06-09 | 2006-01-31 | Childrens Hospital Los Angeles | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
WO2002038611A2 (en) * | 2000-11-09 | 2002-05-16 | Immunolex Laboratories | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins |
EP1426382A1 (de) * | 2002-12-06 | 2004-06-09 | Aventis Behring GmbH | Antivirales menschliches Serum Albumin |
WO2005016260A2 (en) * | 2003-08-08 | 2005-02-24 | The Regents Of The University Of California | Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides |
AU2005271687A1 (en) * | 2004-08-03 | 2006-02-16 | Becton, Dickinson And Company | Use of magnetic material to fractionate samples |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
DK3056568T3 (da) * | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
EP2009101B1 (de) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers |
EP3492488A1 (de) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung |
EP3789400A1 (de) | 2007-09-26 | 2021-03-10 | Chugai Seiyaku Kabushiki Kaisha | Modifizierte antikörperkonstantregion |
JP5334319B2 (ja) * | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
JP4535406B2 (ja) * | 2007-09-28 | 2010-09-01 | 中外製薬株式会社 | 血漿中動態が改善されたグリピカン3抗体 |
KR101643005B1 (ko) | 2007-12-05 | 2016-07-28 | 추가이 세이야쿠 가부시키가이샤 | 항nr10 항체 및 그의 이용 |
US8937047B2 (en) * | 2007-12-19 | 2015-01-20 | General Electric Company | Biokinetics of fast-clearing polypeptides |
US8124725B2 (en) | 2007-12-19 | 2012-02-28 | General Electric Company | PDGF-Rβ binders |
CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
CA2753294A1 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Inc. | Proproteins and methods of use thereof |
TWI544077B (zh) | 2009-03-19 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | Antibody constant region change body |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
PE20120562A1 (es) | 2009-05-15 | 2012-06-06 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-axl |
WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
KR20130009744A (ko) | 2010-01-13 | 2013-01-23 | 에이피티 테라퓨틱스 인코포레이션 | 치료적 아피라제 컨스트럭트, 아피라제 제제 및 제조 방법 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
DK2644698T3 (en) | 2010-11-17 | 2018-01-22 | Chugai Pharmaceutical Co Ltd | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII |
WO2012070964A1 (ru) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Модифицированные олигопептиды с противораковыми свойствами и способ их получения |
SG10201509790YA (en) | 2010-11-30 | 2015-12-30 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly |
MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
EP3939996A1 (de) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten |
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
CN105018442A (zh) * | 2014-04-23 | 2015-11-04 | Apt治疗公司 | 改进的en-腺苷三磷酸双磷酸酶 |
CN113933504A (zh) | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
PT3233921T (pt) | 2014-12-19 | 2021-12-09 | Chugai Pharmaceutical Co Ltd | Anticorpos anti-c5 e processos para a sua utilização |
TWI779010B (zh) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
AU2016224409B2 (en) | 2015-02-27 | 2021-01-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
EP3398965A4 (de) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur förderung der effizienz der reinigung von polypeptid mit fc-region |
AU2017233658B2 (en) | 2016-03-14 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
SG11201801024XA (en) | 2016-08-05 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Therapeutic or preventive compositions for il-8-related diseases |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720765A (en) * | 1970-10-27 | 1973-03-13 | Monsanto Co | Crosslinked protein with acid anhydride as a ruminant feed material |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2340911A1 (de) * | 1973-08-13 | 1975-05-07 | Behringwerke Ag | Tetanus-antigen und verfahren zu seiner herstellung |
US4118379A (en) * | 1974-09-06 | 1978-10-03 | Behringwerke Aktiengesellschaft | Amidated immune globulins and process for preparing them |
US4082507A (en) * | 1976-05-10 | 1978-04-04 | Sawyer Philip Nicholas | Prosthesis and method for making the same |
US4168262A (en) * | 1978-03-13 | 1979-09-18 | Cornell Research Foundation, Inc. | Anhydride modified microbial protein having reduced nucleic acid levels |
US4218539A (en) * | 1978-03-24 | 1980-08-19 | Weltman Joel K | Enzyme conjugates and method of preparation and use |
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
US4501692A (en) * | 1979-07-26 | 1985-02-26 | Syva Company | Charge effects in enzyme immunoassays |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US4749570A (en) * | 1981-12-31 | 1988-06-07 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
IT1150213B (it) * | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
GR81790B (de) * | 1983-04-29 | 1984-12-12 | Omnichem Sa | |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
EP0154316B1 (de) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung |
US4560504A (en) * | 1984-12-06 | 1985-12-24 | Uop Inc. | Carboxyl anchored immobilized antibodies |
US5045303A (en) * | 1985-05-17 | 1991-09-03 | Neorx Corporation | Radiohalogenated small molecules for protein labeling |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5151266A (en) * | 1985-08-20 | 1992-09-29 | Neorx Corporation | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies |
CA1282069C (en) * | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
US5223242A (en) * | 1985-11-05 | 1993-06-29 | The General Hospital Corporation | Negatively charged specific affinity reagents |
JPS62181229A (ja) * | 1985-11-05 | 1987-08-08 | ザ・ゼネラル・ホスピタル・コ−ポレ−シヨン | 負に荷電した特異親和性試薬 |
JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US4931544A (en) * | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
US5034223A (en) * | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
US5084556A (en) * | 1987-10-23 | 1992-01-28 | Genetics Institute, Inc. | Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5162505A (en) * | 1989-09-19 | 1992-11-10 | Centocor | Proteins modified with positively charged carriers and compositions prepared therefrom |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
-
1988
- 1988-02-17 US US07/157,273 patent/US5322678A/en not_active Expired - Fee Related
-
1989
- 1989-02-17 EP EP89102810A patent/EP0329185B1/de not_active Expired - Lifetime
- 1989-02-17 DE DE68914698T patent/DE68914698T2/de not_active Expired - Lifetime
- 1989-02-17 JP JP1036405A patent/JPH0228200A/ja active Pending
- 1989-02-17 AU AU30069/89A patent/AU621342B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0329185A3 (en) | 1990-05-16 |
JPH0228200A (ja) | 1990-01-30 |
AU3006989A (en) | 1989-08-17 |
AU621342B2 (en) | 1992-03-12 |
US5322678A (en) | 1994-06-21 |
EP0329185B1 (de) | 1994-04-20 |
EP0329185A2 (de) | 1989-08-23 |
DE68914698T2 (de) | 1994-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68914698T2 (de) | Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. | |
DE69008891T2 (de) | Lagerung von Materialien. | |
NO902038D0 (no) | Bitumenpolymerblandinger. | |
NO864139L (no) | Polypeptid virksomt ved dannelse av aids-antistoff. | |
DE3879452T2 (de) | Chimaere antikoerper. | |
NO895010D0 (no) | Konstruksjonsmateriale. | |
DE68904679D1 (de) | Elektroplattierung von kleinen partikeln. | |
DE3877862D1 (de) | Bestimmung der ausrichtung von bauteilen. | |
NO892294D0 (no) | Polypeptidforbindelser. | |
DE68924246D1 (de) | Tonerzusammensetzung. | |
DE68912109T2 (de) | Justierung von quadratursignalen. | |
DE68924932T2 (de) | Piezoelektrische Vibrator-Komponente. | |
NO890774D0 (no) | Ekspresjon av hiv-bindende proteiner. | |
DE3863393D1 (de) | Verbesserung der cetanzahl von dieselkraftstoffen. | |
NO892949L (no) | Nye proteiner. | |
ATE125794T1 (de) | Prodrogen von antiinflammatorischen 3-acyl-2- oxindol-1-carboxamiden. | |
DE69019244T2 (de) | Ladungspumpe. | |
NO892948D0 (no) | Modifiserte proteiner. | |
DE3881991D1 (de) | Zusammensetzung von gleitgliedern. | |
DE69002136D1 (de) | Saccharidderivate von protocatechualdehyd. | |
DE68912248D1 (de) | Diuretischer Faktor. | |
DE68915248D1 (de) | Unterscheidung von Bildbereichen. | |
DE3881393D1 (de) | Dehydrobromierung von substituiertem alpha-halocumol. | |
NO874091L (no) | Nye trombolytiske proteiner. | |
IT8705142A0 (it) | Ponte anti-cariche elettrostatiche. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |